Skip to content
Peptigraph home

Mazdutide Phase 2 trial (NCT04904913)

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese Subjects

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
328
actual
Start
8 Jun 2021 (actual)
Primary completion
29 Mar 2023 (actual)
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Design

Arms and doses

NCT04904913 study arms
ArmTypeInterventionsDescription
IBI362 high doseExperimentalDrug: IBI362high dose IBI362 administered subcutaneously (SC) once a week.
IBI362 low doseExperimentalDrug: IBI362Low dose IBI362 administered subcutaneously (SC) once a week.
placeboPlacebo comparatorOther: placeboplacebo administered subcutaneously (SC) once a week.
IBI362 moderate doseExperimentalDrug: IBI362moderate dose IBI362 administered subcutaneously (SC) once a week.
IBI362 extra high doseExperimentalDrug: IBI362extra high dose IBI362 administered subcutaneously (SC) once a week.
Endpoints

Primary endpoint

NCT04904913 primary outcomes
MeasureTime frame
Percent Change from Baseline in Body WeightBaseline ,week 24
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT04904913 secondary outcomes
MeasureTime frame
Percentage of Participants who Achieve ≥5% Body Weight ReductionBaseline, Week 24
Percentage of Participants who Achieve ≥10% Body Weight ReductionBaseline, Week 24
Absolute change from Baseline in body weightBaseline, Week 24
Change from Baseline in Waist CircumferenceBaseline, Week 24
Change from Baseline in BMIBaseline, Week 24
Change from Baseline in HbA1cBaseline, Week 24
Change from Baseline in fasting plasma glucoseBaseline, Week 24
Change from Baseline in systolic blood pressureBaseline, Week 24
Change from Baseline in diastolic blood pressureBaseline, Week 24
Change from Baseline in total cholesterolBaseline, Week 24
Change from Baseline in low-density lipoprotein cholesterolBaseline, Week 24
Change from Baseline in high-density lipoprotein cholesterolBaseline, Week 24
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

The Chinese overweight and obesity phase 2 interim analysis

Adults with a BMI of 24 or more plus hyperphagia or a comorbidity, or a BMI of 28 or more, were randomised 3:1:3:1:3:1 to mazdutide or placebo, with percentage weight change at week 24 as the primary endpoint.[2]

A total of 248 participants were randomised: 62 to 3 mg, 63 to 4.5 mg, 61 to 6 mg and 62 to placebo.[2]

Week 24 weight results

Weight changed by -6.7%, -10.4% and -11.3% with mazdutide 3, 4.5 and 6 mg, against +1.0% with placebo.[2]

Diarrhoea, nausea and upper respiratory tract infection were the most common adverse events.[2]

Sources

  1. 1A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese SubjectsClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.Nature communications · 2023PMID 38092790Accessed 2 Oct 2026

Found an error? Report a correction.